Similarly, Kitai et al. reported that combinations of MEK and FGFR inhibitors, may be effective against mesenchymal-like KRAS-mutated non-small cell lung carcinoma [12]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.